LegisTrack
Back to all bills
HRES 732119th CongressIntroduced

Expressing support for the designation of September 30, 2025, as "Rare Cancer Day" to highlight the challenges patients with rare cancers face and to raise awareness and support efforts to improve early diagnosis and treatment.

Introduced: Sep 17, 2025
Healthcare
Standard Summary
Comprehensive overview in 1-2 paragraphs

H. Res. 732 is a House resolution introduced in the 119th Congress by Rep. Kelly (PA) with co-sponsors Rep. Wasserman Schultz, Rep. Fitzpatrick, and Rep. Dingell. The resolution expresses support for designating September 30, 2025, as “Rare Cancer Day.” Its purpose is to highlight the challenges faced by patients with rare cancers, raise public awareness, and support efforts to improve early diagnosis and treatment. The resolution is symbolic and does not itself create new law or spending, but it signals congressional support for awareness, collaboration with the medical and scientific communities, and potential funding for research and treatment. The measure presents several factual statements about rare cancers (including statistics on prevalence, pediatric cancers, survival, and diagnostic challenges) and calls for awareness-building, partnerships, and funding to improve detection and develop better treatments.

Key Points

  • 1Designate September 30, 2025 as “Rare Cancer Day” to raise awareness and support efforts to improve early diagnosis and treatment.
  • 2Recognize the challenges of detecting and diagnosing rare cancers for patients, providers, and scientists.
  • 3Acknowledge that rare cancers affect a substantial portion of cancer patients and that all pediatric cancers are rare.
  • 4Encourage awareness-raising about rare cancer symptoms to promote earlier detection and improve survival rates, and promote partnerships with the medical and scientific communities.
  • 5Support dedication of funding to explore cures and treatments for rare cancers.

Impact Areas

Primary group/area affected: Individuals with rare cancers (including pediatric patients) and their families; oncology clinicians and researchers who diagnose and treat these cancers.Secondary group/area affected: Public health and patient-advocacy communities; medical institutions and scientists; policymakers evaluating cancer research and awareness initiatives.Additional impacts: Signals congressional support that could influence awareness campaigns, advocacy funding priorities, and potential future policy or funding discussions related to rare cancers; no new mandatory spending is created by a resolution, but it could bolster efforts and collaborations aiming to improve diagnosis and treatment.
Generated by gpt-5-nano on Oct 2, 2025